ORIGINAL RESEARCH PAPER
Volume - 14 | Issue - 01 | January - 2025 | PRINT ISSN No. 2277 - 8179 | DOI : 10.36106/ijsr
INTERNATIONAL JOURNAL OF SCIENTIFIC RESEARCH

WOODEN CHEST SYNDROME: A CLINICAL REVIEW

Internal Medicine
Jeffrey Allen Tyre M.D.,
Chandni Patel
Vasudha Veligatla
Natalee Marie Tyre
Zequen Chen
Suhani Patel

ABSTRACT

Wooden Chest Syndrome (WCS), also known as opioid-induced chest wall rigidity, is a potentially fatal condition characterized by respiratory compromise due to severe rigidity of the chest wall musculature. It typically arises as a complication of high-dose or rapid administration of synthetic opioid agonists, particularly fentanyl, in critical care or illicit use settings. The primary clinical manifestations of WCS include elevated airway pressure, reduced chest wall compliance, hypercapnia, hypoxemia, and episodes of 'breath-holding spells.' These effects may culminate in hypoventilation and severe respiratory failure if untreated. Key risk factors for WCS include high-dose opioid administration, rapid intravenous bolus injection, concurrent use of neuromuscular blockers or sedatives, and pre-existing respiratory or neuromuscular conditions. The underlying pathophysiology involves opioid-induced activation of central nervous system pathways that heighten skeletal muscle tone, particularly in the chest wall and diaphragm, leading to impaired ventilatory mechanics. Management of WCS requires prompt recognition and intervention. Initial steps include discontinuing fentanyl administration to prevent further exacerbation of symptoms, alongside providing supportive care to stabilize the patient. Specific treatments involve administering opioid antagonists like naloxone to reverse the opioid effect and facilitate chest wall relaxation. Adjunctive measures, such as neuromuscular blocking agents and mechanical ventilation, may be necessary in severe cases to restore adequate ventilation and oxygenation. Preventative strategies include cautious opioid dosing, slower infusion rates, and close monitoring of high-risk patients during opioid administration. This article aims to enhance clinician awareness of Wooden Chest Syndrome by detailing its clinical presentation, risk factors, pathophysiology, diagnostic markers, and treatment modalities. Greater understanding and early recognition of this condition are essential to mitigate its associated morbidity and mortality.

KEYWORDS

INTRODUCTION AND BACKGROUND

Fentanyl

Fentanyl is a synthetic mu-opioid receptor (MOR) agonist being used more frequently for analgesia and anesthesia. Fentanyl is highly lipophilic with low molecular weight, leading to rapid distribution to anatomical areas with high perfusion, including the brain, with ease in crossing various cell membranes [1]. Production of fentanyl has not only been increasingly produced by pharmaceutical companies but for illicit use as well, with many drug abusers choosing fentanyl over heroin [1]. Fentanyl is commonly used in patients who are mechanically ventilated and patients in severe pain. Administration of fentanyl can occur intramuscularly, intranasal, intrathecally, intravenously, and via a transdermal patch [2].

Mechanism of Action

Fentanyl stimulates mu-opioid ligand receptors to produce the desired analgesic and anesthetic effects [1,2,3]. These ligand receptors are a subset of G-Protein Coupled Receptors [4]. The rewarding impact of fentanyl occurs when the MORs in the ventral tegmentum are stimulated and result in dopamine release [5]. There are also MORs expressed in various regions of the spinal cord, and their stimulation inhibits ascending neuronal signals, contributing to the analgesic effect of Fentanyl [6]. MOR stimulation in the arousal pathway also leads to decreased neuronal transmission, reducing consciousness [7].

Adverse Effects of Fentanyl

Fentanyl, the most widely used opioid, comes with its daunting adverse effects. The most significant adverse effect that can occur with the use of this drug is severe respiratory depression. This happens due to the drug diminishing the brainstem's respiratory center sensitivity to carbon dioxide levels, potentially leading to apnea and even death. Fentanyl produces other typical central nervous system effects like fatigue, bradycardia, sedation, nausea, vomiting, dizziness, and constipation. Because fentanyl is metabolized predominantly by the cytochrome P450 enzyme system in the liver, its breakdown can be influenced by other medications that interact with the enzyme's activity. This article will highlight and discuss the rare adverse effect of 'Wooden Chest Syndrome.' This is a condition of chest wall rigidity that can arise after intravenous administration of fentanyl, pertaining to high dosing and rapid administration [8].

What is Wooden Chest Syndrome?

Wooden Chest Syndrome (WCS) is a rare but potentially life-threatening complication that occurs during intravenous administration of fentanyl, typically seen in critical care environments or with illicit use of the drug. It is a condition characterized by chest wall rigidity where the ability to ventilate becomes impaired, potentially leading to hypoxia and respiratory failure [9]. Both timing and intensity of muscle rigidity are closely linked to the dose of fentanyl given. Higher dosing or rapid intravenous administration increases the severity of chest wall rigidity [10]. In 1953, Hamilton and Cullen were the first to identify Wooden Chest Syndrome, describing it as opioid-induced chest wall rigidity observed during their research on opioid pharmacology [11]. Although WCS is rare, neonates and pediatric populations in the critical care setting are the most affected. Key signs include elevated airway pressure, clenched jaw, laryngeal spasms, rigid extremities, tightened thoracic, abdominal, and neck muscles, and 'breath-holding spells.' In such cases, the chest wall rigidity may be so severe that manual ventilation becomes ineffective [9,10]. This article will highlight Wooden Chest Syndrome's risk factors, pathophysiology, clinical presentation, medical management, and prevention strategies.

Review

Risk Factors

Any MOR agonist, such as fentanyl, increases the risk of Wooden Chest Syndrome. Rapid Infusion and/or high doses of opioids can lead to rigidity of the diaphragm and other chest wall muscles [10,11]. Co-administration with different medications, such as muscle relaxants or other sedative agents, can also lead to WCS [10,11]. Musculoskeletal conditions such as Guillain-Barre Syndrome, Amyotrophic Lateral Sclerosis, etc., can increase the risk of developing WCS [10,11]. Theoretically, liver failure could potentially lead to increased risk due to decreased metabolism of opiates.

Pathophysiology of Wooden Chest Syndrome

The pathophysiology of WCS occurs due to the stimulation of mu-opioid receptors in the brainstem and spinal cord [14]. The mu-opioid

receptors in the brainstem are believed to be the primary cause of chest wall rigidity. The stimulation of these receptors activates the inhibitory G-Protein Coupled Receptor, leading to reduced gabaergic inhibition in the brain stem [15]. Therefore, excitatory pathways are disinhibited in motor control areas such as the locus coeruleus and medullary reticular formation [15]. Concurrently, glutamate has increased excitatory action, particularly in intercostal muscles and diaphragm areas and possibly in other regions innervated by corticospinal pathways [15]. The increased excitatory response by musculoskeletal neurons leads to chest wall rigidity and reduced compliance for adequate pulmonary function.

Clinical Presentation of Wooden Chest Syndrome

Wooden Chest Syndrome is characterized by severe rigidity of the chest wall muscles, leading to compromised ventilation and respiratory failure. It is a complication commonly seen in anesthesiology, pulmonology, and critical care departments and can affect any age group exposed to intravenous fentanyl or illicit drug use [16]. Clinically, patients often exhibit marked difficulty in spontaneous and assisted breathing, which may present as high airway pressures during mechanical ventilation, hypoxia, and respiratory acidosis. Physical findings include tense abdominal muscles, a locked jaw, stiff extremities, and breath-holding spells. In severe cases, WCS can be associated with cardiovascular instability, such as hypertension and tachycardia. The syndrome is typically triggered by the administration of high doses or rapid infusion of synthetic opioids, particularly fentanyl, due to its high lipid solubility and rapid activation of mu-opioid receptors [16]. Timely recognition and intervention, such as using neuromuscular blocking agents or opioid antagonists, are critical for preventing life-threatening complications [17]

Wooden Chest Syndrome Medical Management

The medical management of Wooden Chest Syndrome focuses on stopping fentanyl or any other opioids being used and promptly addressing the life-threatening chest wall rigidity and ventilatory failure caused by opioid-induced muscle rigidity. Initial treatment often involves the administration of neuromuscular blocking agents, such as succinylcholine or rocuronium, to counteract the rigidity and allow adequate ventilation. Opioid antagonists like naloxone can also reverse the effects of fentanyl; however, their use must be cautious due to the risk of precipitating withdrawal or worsening airway complications [16,17]. Sedative agents such as dexmedetomidine or benzodiazepines may help reduce rigidity by modifying central nervous system excitation. Supportive measures, including mechanical ventilation with adjustments to overcome high airway pressures, are crucial for stabilizing the patient during acute episodes. Early recognition and a multidisciplinary approach involving anesthesiologists and critical care teams are key to reducing morbidity and mortality associated with WCS. Awareness of possible complications, such as renal failure due to rhabdomyolysis from sustained muscle contraction, is crucial.

Prevention of Wooden Chest Syndrome

Since Wooden Chest Syndrome (WCS) is a rare but potentially life-threatening complication associated with fentanyl administration, promoting awareness among medical professionals regarding its risk factors and prevention strategies is essential. Early recognition and identifying at-risk populations are crucial for mitigating their occurrence. Vulnerable groups include individuals over the age of 60, patients with underlying metabolic syndrome, or those with neurological disorders such as essential tremor or Parkinson's disease. Additional risk factors include the concurrent use of certain antidepressants [18]. Prophylactic measures, including the availability of antidotes such as naloxone and oxygen, should be prioritized for these high-risk populations, particularly among active opioid users. Enhanced injection practices—such as administering a test dose to assess patient tolerance, utilizing safe injection sites for supervised administration, and employing chaperones to provide immediate intervention—are also recommended [18,19].

Given the rapid onset and severity of WCS, meticulous attention to dosing and administration techniques is paramount. High doses and rapid intravenous bolus injections of fentanyl are strongly associated with WCS; therefore, opioids should be administered as slow infusions at the lowest effective therapeutic dose to minimize risk [20-22]. Furthermore, non-μ-opioid receptor prophylaxis agents, including α1-adrenergic antagonists, α2-adrenergic agonists, and anticholinergic agents, may prevent WCS [19].

By adopting these preventive strategies, including cautious opioid administration and ensuring readiness for prompt intervention, clinicians may significantly reduce the incidence of WCS and improve patient safety during fentanyl use.

CONCLUSION

Wooden Chest Syndrome represents a rare but severe complication of opioid administration, particularly with fentanyl. As the use of fentanyl continues to rise in both clinical and illicit settings, heightened awareness of this condition is imperative. The unique interplay between opioid pharmacology and the pathophysiology of chest wall rigidity underscores the need for vigilance during fentanyl use, particularly in at-risk populations.

Through early recognition and prompt intervention—including the use of opioid antagonists, neuromuscular blocking agents, and supportive care—clinicians can mitigate the life-threatening consequences of WCS. Preventative measures, such as cautious dosing, slow infusion rates, and patient-specific risk assessment, are pivotal in reducing its incidence. Future research should focus on refining strategies for early diagnosis, exploring alternative opioid administration methods, and developing adjunctive therapies to improve patient outcomes further. Ultimately, the integration of these approaches into practice can significantly enhance the safety of opioid use and reduce the burden of WCS in clinical and community settings.

REFERENCES

1. Bird, H. E., Huhn, A. S., & Dunn, K. E. (2023). Fentanyl Absorption, Distribution, Metabolism, and Excretion: Narrative Review and Clinical Significance Related to Illicitly Manufactured Fentanyl. Journal of addiction medicine, 17(5), 503–508. https://doi.org/10.1097/ADM.0000000000001185
2. Ramos-Matos CF, Bistas KG, Lopez-Ojeda W. Fentanyl. [Updated 2023 May 29]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK459275/
3. Kelly, E., Sutcliffe, K., Cavallo, D., Ramos-Gonzalez, N., Alhosan, N., & Henderson, G. (2023). The anomalous pharmacology of fentanyl. British journal of pharmacology, 180(7), 797–812. https://doi.org/10.1111/bph.15573
4. Faouzi, A., Varga, B. R., & Majumdar, S. (2020). Biased Opioid Ligands. Molecules (Basel, Switzerland), 25(18), 4257. https://doi.org/10.3390/molecules25184257
5. Fields, H. L., & Margolis, E. B. (2015). Understanding opioid reward. Trends in Neurosciences, 38(4), 217-225. https://doi.org/10.1016/j.tins.2015.01.002
6. Han, J., Sun, Z., Hu, W., & Liu, Z. (2024). The Role of Mu Opioid Receptors of the Medial Prefrontal Cortex in Modulation of Analgesia Induced by Acute Restraint Stress in Male Mice. International Journal of Molecular Sciences, 25(18), 9774. https://doi.org/10.3390/ijms25189774
7. American Society of Anesthesiologists. (n.d.). Molecular Mechanisms of Opioid Receptor-dependent Signaling and Behavior. Retrieved from https://pubs.asahq.org/anesthesiology/article/85/3/574/35716
8. Stanley, T. H. (2014). Fentanyl. Journal of Pain and Symptom Management, 45(3), 465-470. https://doi.org/10.1016/j.jpain.2014.08.010
9. Rosal, N. R., Thelmo, F. L., Tzarnas, S., DiCalvo, L., Tariq, S., & Grossman, C. (2021). Wooden chest syndrome: A case report of fentanyl-induced chest wall rigidity. Journal of Investigative Medicine High Impact Case Reports. https://doi.org/10.1177/23247096211034036
10. Sahni, R. (2023). Wooden Chest Syndrome Secondary to Suspected Illicit Fentanyl Use. Washington County EMS. https://www.washingtoncountyor.gov/hhs/documents/wooden-chest-syndrome-secondary-suspected-illicit-fentanyl/download?inline
11. William K. Hamilton, Stuart C. Cullen; Effect of LevalloephanTaetrate Upon Opiate Induced Respiratory Depression. Anesthesiology 1953; 14:550–554 https://doi.org/10.1097/00000542-195311000-00002
12. Dahan, A., et al. (2020). The Role of Mu-Opioid Receptor Stimulation in Opioid-Induced Rigidity. Pain Reports. Retrieved from PubMed
13. American Society of Anesthesiologists. Opioid Mechanisms in Muscle Rigidity. Retrieved from ASA Publications
14. Wilson, K. L., & Rehder, K. (2020). Pathophysiology and clinical considerations of opioid-induced chest wall rigidity. Anesthesiology Clinics, 38(3), 503-517. https://doi.org/10.1016/j.anclin.2020.05.003
15. Kim, H. K., & Nelson, L. S. (2015). Opioid-induced rigidity: Pathophysiology and implications for clinical management. Journal of Neuroscience Research, 93(7), 995-1001. https://doi.org/10.1002/jnr.23575
16. Rosal, N. R., Thelmo, F. L., Tzarnas, S., DiCalvo, L., Tariq, S., & Grossman, C. (2021). Wooden chest syndrome: A case report of fentanyl-induced chest wall rigidity. Journal of Investigative Medicine High Impact Case Reports, 9(3), 1–4. https://doi.org/10.1177/23247096211034036
17. Dimitriou, V., Zogogiannis, I., Liotiri, D., Wambi, F., & Tawfeeq, N. (2014). Case report on fentanyl-induced muscle rigidity. Middle East Journal of Anesthesiology, 22(6), 619–622.
18. Buxton, J. A., Gauthier, T., Kinshella, M. L. W., & Godwin, J. (2018). A 52-year-old man with fentanyl-induced muscle rigidity. CMAJ, 190(17), E539–E541. https://doi.org/10.1503/cmaj.171468
19. Torralva, R., & Janowsky, A. (2019). Noradrenergic mechanisms in fentanyl-mediated rapid death explain failure of naloxone in the opioid crisis. Journal of Pharmacology and Experimental Therapeutics, 371(2), 453–475. https://doi.org/10.1124/jpet.119.258566
20. Ham, S., Lee, B., Ha, T., et al. (2016). Recurrent desaturation events due to opioid-induced chest wall rigidity after low dose fentanyl administration. Korean Journal of Critical Care Medicine, 31(2), 118–122. https://doi.org/10.4266/kjccm.2016.31.2.118
21. Malik, I., Wilks, J., Singh, P., et al. (2018). Wooden Chest Syndrome: A case report of fentanyl-induced chest wall rigidity. Journal of Clinical Anesthesia and Pain Medicine, 2(1), 013. https://doi.org/10.35841/clinical-anesthesia-pain-medicine.2.1.13
22. van der Schrier, R., Dahan, J. D. C., Boon, M., Sarton, E., van Velzen, M., Niesters, M., & Dahan, A. (2022). Advances in reversal strategies of opioid-induced respiratory toxicity. Anesthesiology, 136(4), 618–632. https://doi.org/10.1097/ALN.0000000000004126